Nature Communications (Jul 2024)

Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems

  • Maksymilian Prondzynski,
  • Paul Berkson,
  • Michael A. Trembley,
  • Yashasvi Tharani,
  • Kevin Shani,
  • Raul H. Bortolin,
  • Mason E. Sweat,
  • Joshua Mayourian,
  • Dogacan Yucel,
  • Albert M. Cordoves,
  • Beatrice Gabbin,
  • Cuilan Hou,
  • Nnaemeka J. Anyanwu,
  • Farina Nawar,
  • Justin Cotton,
  • Joseph Milosh,
  • David Walker,
  • Yan Zhang,
  • Fujian Lu,
  • Xujie Liu,
  • Kevin Kit Parker,
  • Vassilios J. Bezzerides,
  • William T. Pu

DOI
https://doi.org/10.1038/s41467-024-50224-0
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Human iPSC-derived cardiomyocytes (hiPSC-CMs) have proven invaluable for cardiac disease modeling and regeneration. Challenges with quality, inter-batch consistency, cryopreservation and scale remain, reducing experimental reproducibility and clinical translation. Here, we report a robust stirred suspension cardiac differentiation protocol, and we perform extensive morphological and functional characterization of the resulting bioreactor-differentiated iPSC-CMs (bCMs). Across multiple different iPSC lines, the protocol produces 1.2E6/mL bCMs with ~94% purity. bCMs have high viability after cryo-recovery (>90%) and predominantly ventricular identity. Compared to standard monolayer-differentiated CMs, bCMs are more reproducible across batches and have more mature functional properties. The protocol also works with magnetically stirred spinner flasks, which are more economical and scalable than bioreactors. Minor protocol modifications generate cardiac organoids fully in suspension culture. These reproducible, scalable, and resource-efficient approaches to generate iPSC-CMs and organoids will expand their applications, and our benchmark data will enable comparison to cells produced by other cardiac differentiation protocols.